Phase II Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent Glioblastoma

Trial Profile

Phase II Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Sildenafil (Primary) ; Sorafenib (Primary) ; Valproic acid (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018, as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned number of patients changed from 51 to 66 as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned initiation date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top